Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Colon Cancer
New colon cancer study results from University of Michigan described
June 17th, 2009
According to recent research published in the journal Molecular Pharmaceutics, "Anti-TAG-72 monoclonal antibodies target the tumor-associated glycoprotein (TAG)72 in various solid tumors. This study evaluated the use of anti-TAG-72 monoclonal antibodies, both murine CC49 and humanized CC49 (HuCC49 Delta C(H)2), for near-infrared fluorescent (NIR) tumor imaging in colorectal cancer xenograft models." "The murine CC49 and HuCC49 Delta C(H)2 were conjugated with Cy7 monofunctional N-hydroxysuccinimide ester (Cy7-NHS). Both in vitro and in vivo anti-TAG-72 antibody binding studies were performed. The in vitro study utilized the human colon adenocarcinoma cell line...
Source: Immunotherapy Weekly (2009-06-17)
|
